About Myozyme^TM

Myozyme^TM (alglucosidase alfa) has been approved by the EMEA in March 2006 and by the FDA in April 2006 for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Pompe disease. The product is the first treatment ever approved for Pompe disease and one of the first for an inherited muscle disorder.

Myozyme^TM is reimbursed in Belgium since the 1st of May 2007.

Download Dutch RIZIV reimbursement form (PDF).

Download French INAMI reimbursement form (PDF).

Myozyme^TM is the recombinant form of human α-glucosidase and is produced by recombinant DNA technology using Chinese Hamster Ovary (CHO) cell culture. It targets the underlying cause of the disease by replacing the deficient enzyme (α-glucosidase).

The recommended dosage is 20 mg/kg of body weight administered once every two weeks by IV infusion.

Please see the full prescribing information in Dutch or in French (PDF) for Myozyme^TM.

To access information about the steps required to reconstitute and administer Myozyme see Reconstitution and Administration.